Patients with baseline qAnti-HBc levels ≥ 30,000 IU/mL had significantly higher response rates, more HBV DNA suppression, and better hepatitis control in PegIFN-α treatment28, but the qAnti-HBc during PegIFN treatment maintained unchanged, and this phenomenon devalued qAnti-HBc monitoring significance of the PegIFN-α response. The gene discussed is KRT88P; the disease is hepatitis A virus infection.